Skip to main content

Loading market data...

CYTK

Cytokinetics, Incorporated

NASDAQ • United states

$63.95

+$1.30

(+2.08%)

Source: Yahoo Finance · Quote time Oct 20, 2026 20:00 GMT+0000

Catalyst Evidence

No verified catalyst stored yet

Click “View” to see the stored chain of evidence (if available).

Management
Credibility
Score

Cytokinetics, Incorporated (CYTK)

Unavailable

Quotes may be delayed

$8.89B

Market Cap

1,050,322

Volume

Unavailable

P/E Ratio

Unavailable

Div Yield

Cytokinetics, Incorporated Price Chart

Loading price history…

Management Credibility Analysis

Unavailable

Verified Management Score Unavailable

Management credibility requires sourced guidance and earnings history.

Upcoming Catalysts

Verified event feed

Verified Catalysts Unavailable

No sourced upcoming event feed is configured for this stock yet.

Company profile

No description available

Chief executive: Not disclosed
Headquarters: 350 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO, CA
Founded: Not disclosed

📈 Company Timeline

Major business events

Positive

Negative

Neutral

28 Aug 2026

Cytokinetics, Incorporated reported Another company event

Cytokinetics, Incorporated filed an 8-K covering another company event, supporting financial statements or exhibits.

14 Aug 2026

Large-holder ownership filing

A holder reported or amended a beneficial ownership position of more than 5% in Cytokinetics, Incorporated.

13 Aug 2026

Cytokinetics, Incorporated reported Another company event

Cytokinetics, Incorporated filed an 8-K covering another company event.

7 Aug 2026

Cytokinetics, Incorporated filed Form 10-Q

Cytokinetics, Incorporated submitted Form 10-Q to the SEC for the period ending Jun 30, 2026.

7 Aug 2026

Cytokinetics, Incorporated reported Operating or financial results

Cytokinetics, Incorporated filed an 8-K covering operating or financial results, supporting financial statements or exhibits.

Capital Structure & Financial Position

Financial strength and liquidity analysis

Cash and equivalents (USD)$255.27M

Total assets (USD)$1.92B

Total liabilities (USD)$2.10B

Shareholders' equity (USD)−$173.49M

Long-term debt (USD)$248.20M

Debt due within a year (USD)$27.36M

Source: SEC EDGAR company facts (opens in a new tab) Balance sheet dated 30 Jun 2026

Peer Comparison - Health Care

Company	Price	Market Cap
LLY - Eli Lilly and Company	$1,276.13 Yahoo Finance	$1.20T
JNJ - Johnson & Johnson	$256.74 Yahoo Finance	$618.71B
ABBV - AbbVie Inc.	$284.80 Yahoo Finance	$503.28B
UNH - UnitedHealth Group Incorporated	$418.43 Yahoo Finance	$375.58B
MRK - Merck & Co., Inc.	$148.55 Yahoo Finance	$366.50B

📋 Corporate Actions

Recent and upcoming corporate events

Verified Corporate Actions Unavailable

Dividend, buyback, split, and spin-off feeds are not ingested for this stock yet.

Financials

Financial statements and key metrics analysis

Quarter	Revenue (USD)	Operating income	Net income	Diluted EPS (USD)	Filed
Q2 2026	$28.62M	−$179.17M	−$198.76M	−$1.50	10-Q · 6 Aug 2026
Q1 2026	$19.36M	−$183.62M	−$206.03M	−$1.67	10-Q · 5 May 2026
Q4 2025	$17.76M	−$178.37M	−$183.03M	Unavailable	10-K · 26 Feb 2026
Q3 2025	$1.94M	−$166.76M	−$306.18M	−$2.55	10-Q · 5 Nov 2025
Q2 2025	$66.77M	−$111.51M	−$134.37M	−$1.12	10-Q · 7 Aug 2025
Q1 2025	$1.58M	−$155.63M	−$161.38M	−$1.36	10-Q · 6 May 2025

Source: SEC EDGAR company facts (opens in a new tab)

Analyst Consensus

Buy

Target: $110.40

72.6% upside potential

📈

Strong Buy

Unavailable

👍

Buy

15

⏸️

Hold

1

📉

Sell

0

16 analysts covering this stock

Source: Nasdaq analyst research (opens in a new tab) Retrieved 21 Oct 2026, 01:49 UTC Targets range 81.00–146.00 Ratings are third-party opinions, not advice.

💰 Upcoming Dividends

Next dividend payments

Verified Dividend Data Unavailable

Dividend calendar data is not ingested for this stock yet.

Guidance Evolution

Verified Guidance History Unavailable

Verified company guidance history is not ingested for this stock yet.

💼 Director Transactions

Recent insider activity

20

Oct 2026

Malik Fady Ibraham

EVP Research & Development

Option exercise

$7.80 per share

3,500 shares

20

Oct 2026

Malik Fady Ibraham

EVP Research & Development

Open-market sale

$64.01 per share

3,500 shares

16

Oct 2026

Wysenski Nancy

Director

Grant or award

$63.92 per share

97 shares

16

Oct 2026

Kaye Edward M. MD

Director

Grant or award

$63.92 per share

195 shares

16

Oct 2026

Harrington Robert Arthur

Director

Grant or award

$63.92 per share

195 shares

16

Oct 2026

Daly James M

Director

Grant or award

$63.92 per share

195 shares

16

Oct 2026

WIERENGA WENDELL

Director

Grant or award

$63.92 per share

97 shares

16

Oct 2026

HENDERSON JOHN T

Director

Grant or award

$63.92 per share

352 shares

12

Oct 2026

Blum Robert I

Director, President & CEO

Option exercise

$10.60 per share

7,500 shares

12

Oct 2026

Blum Robert I

Director, President & CEO

Open-market sale

$62.88 per share

7,500 shares

Top Shareholders

Blackrock, Inc.

20,094,362 shares

21.431% change

6/30/2026

T. Rowe Price Investment Management, Inc.

18,718,498 shares

6.817% change

6/30/2026

Vanguard Group Inc

12,048,131 shares

1.614% change

12/31/2025

Wellington Management Group Llp

6,931,770 shares

-13.456% change

6/30/2026

Vanguard Portfolio Management Llc

6,711,799 shares

14.854% change

6/30/2026

State Street Corp

6,494,233 shares

13.038% change

6/30/2026

Vanguard Capital Management Llc

6,117,515 shares

11.458% change

6/30/2026

Fmr Llc

5,031,782 shares

-53.075% change

6/30/2026

Avoro Capital Advisors Llc

4,999,999 shares

50% change

6/30/2026

Bank Of America Corp /De/

4,635,709 shares

48.322% change

6/30/2026

Source: Nasdaq institutional holdings (opens in a new tab) Observed 21 Oct 2026, 01:49 UTC· 1 day ago

Research coverage and investment tools

Cytokinetics, Incorporated (CYTK) is a stock listed on the Nasdaq in the United States, in the Health Care sector (Biotechnology: Pharmaceutical Preparations). Its last price was US$63.95 on 20 Oct 2026. That is 28% of the way from its 52-week low of US$54.30 to its 52-week high of US$88.31. Its market capitalisation was US$8.89 billion at that price.

Watch Add to portfolio Set an alert Compare Position size

How position sizing works Dividend yield and total return

Quarter	Revenue	Operating income	Net income	Diluted EPS	Gross margin	Operating margin	Free cash flow	Filed
Q2 2026	$28.62M	−$179.17M	−$198.76M	−$1.50	—	-626.0%	−$164.17M	10-Q · 6 Aug 2026 (opens in a new tab)
Q1 2026	$19.36M	−$183.62M	−$206.03M	−$1.67	—	-948.7%	−$151.39M	10-Q · 5 May 2026 (opens in a new tab)
Q4 2025	$17.76M	−$178.37M	−$183.03M	Unavailable	—	-1,004.6%	−$148.30M	10-K · 26 Feb 2026 (opens in a new tab)
Q3 2025	$1.94M	−$166.76M	−$306.18M	−$2.55	—	-8,613.4%	−$116.86M	10-Q · 5 Nov 2025 (opens in a new tab)
Q2 2025	$66.77M	−$111.51M	−$134.37M	−$1.12	—	-167.0%	−$132.38M	10-Q · 7 Aug 2025 (opens in a new tab)
Q1 2025	$1.58M	−$155.63M	−$161.38M	−$1.36	—	-9,856.3%	−$137.28M	10-Q · 6 May 2025 (opens in a new tab)

Cash and equivalents: $255.27M
Total assets: $1.92B
Total liabilities: $2.10B
Shareholders' equity: −$173.49M
Long-term debt: $248.20M
Debt due within a year: $27.36M

8-K · 28 Aug 2026

Cytokinetics, Incorporated reported Another company event (opens in a new tab)

Cytokinetics, Incorporated filed an 8-K covering another company event, supporting financial statements or exhibits.
SCHEDULE 13G/A · 14 Aug 2026

Large-holder ownership filing (opens in a new tab)

A holder reported or amended a beneficial ownership position of more than 5% in Cytokinetics, Incorporated.
8-K · 13 Aug 2026

Cytokinetics, Incorporated reported Another company event (opens in a new tab)

Cytokinetics, Incorporated filed an 8-K covering another company event.
10-Q · 7 Aug 2026

Cytokinetics, Incorporated filed Form 10-Q (opens in a new tab)

Cytokinetics, Incorporated submitted Form 10-Q to the SEC for the period ending Jun 30, 2026.
8-K · 7 Aug 2026

Cytokinetics, Incorporated reported Operating or financial results (opens in a new tab)

Cytokinetics, Incorporated filed an 8-K covering operating or financial results, supporting financial statements or exhibits.

Insider	Date	Transaction	Shares	Average price	Filing
Malik Fady Ibraham EVP Research & Development	20 Oct 2026	Option exercise (M)	+3,500	$7.80	Form 4 (opens in a new tab)
Malik Fady Ibraham EVP Research & Development	20 Oct 2026	Open-market sale (S)	−3,500	$64.01	Form 4 (opens in a new tab)
Wysenski Nancy Director	16 Oct 2026	Grant or award (A)	+97	$63.92	Form 4 (opens in a new tab)
Kaye Edward M. MD Director	16 Oct 2026	Grant or award (A)	+195	$63.92	Form 4 (opens in a new tab)
Harrington Robert Arthur Director	16 Oct 2026	Grant or award (A)	+195	$63.92	Form 4 (opens in a new tab)
Daly James M Director	16 Oct 2026	Grant or award (A)	+195	$63.92	Form 4 (opens in a new tab)
WIERENGA WENDELL Director	16 Oct 2026	Grant or award (A)	+97	$63.92	Form 4 (opens in a new tab)
HENDERSON JOHN T Director	16 Oct 2026	Grant or award (A)	+352	$63.92	Form 4 (opens in a new tab)
Blum Robert I Director, President & CEO	12 Oct 2026	Option exercise (M)	+7,500	$10.60	Form 4 (opens in a new tab)
Blum Robert I Director, President & CEO	12 Oct 2026	Open-market sale (S)	−7,500	$62.88	Form 4 (opens in a new tab)

Institution	Report date	Shares	Change
Blackrock, Inc.	6/30/2026	20,094,362	21.431%
T. Rowe Price Investment Management, Inc.	6/30/2026	18,718,498	6.817%
Vanguard Group Inc	12/31/2025	12,048,131	1.614%
Wellington Management Group Llp	6/30/2026	6,931,770	-13.456%
Vanguard Portfolio Management Llc	6/30/2026	6,711,799	14.854%
State Street Corp	6/30/2026	6,494,233	13.038%
Vanguard Capital Management Llc	6/30/2026	6,117,515	11.458%
Fmr Llc	6/30/2026	5,031,782	-53.075%
Avoro Capital Advisors Llc	6/30/2026	4,999,999	50%
Bank Of America Corp /De/	6/30/2026	4,635,709	48.322%

Previous close: 62.65 USD
Day range: 62.88 – 64.76 USD
52-week range: 54.30 – 88.31 USD
Volume: 1,050,322
Market cap: $8.89B
Average volume: 1,921,852
EPS (FY 2025, diluted): −6.54 USD
Shares outstanding: 139.02M
Beta (5Y monthly): 0.46

Price, ranges and volume: Yahoo Finance (opens in a new tab) Observed 20 Oct 2026, 20:00 UTC· 1 day ago

Average volume, P/E and shares: Nasdaq (opens in a new tab) Observed 22 Oct 2026, 06:21 UTC· 1 hour ago

EPS: SEC EDGAR company facts (opens in a new tab)

Beta: 5 years of monthly returns against the S&P 500, calculated from Yahoo Finance prices. Market cap is the price × shares outstanding.

This research is not available for CYTK yet

Guidance history

IMPORTANT FINANCIAL DISCLAIMER: The information provided on this platform is for educational and informational purposes only and should not be construed as investment advice. All investments involve risk, including potential loss of principal. Past performance does not guarantee future results. Take Profits is not a registered investment advisor and does not provide personalized investment advice. Users should conduct their own research and consult with qualified financial professionals before making investment decisions. Market data may be delayed and is provided by third-party sources.